|View printer-friendly version|
|Array BioPharma Announces Five Abstracts Selected for Presentation at 2011 AACR Annual Meeting|
BOULDER, Colo., Apr 01, 2011 (BUSINESS WIRE) --
Array BioPharma Inc. (NASDAQ: ARRY) today announced that five abstracts have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held from April 2-6, 2010, at the Orange County Convention Center in Orlando, Fla. Presentations will disclose new findings about its anti-cancer programs: ARRY-380, ARRY-543, ARRY-520 and two emerging programs for cFMS and Chk1 inhibition.
The abstracts can be accessed through the AACR website, www.aacr.org. Abstract titles are provided below, however, please note that according to AACR policy, all data is embargoed until the time of the beginning of the presentation. All posters and presentations will be available as a PDF after they are presented on Array's website at www.arraybiopharma.com.
ARRY-543 / ErbB-family Inhibitor:
ARRY-380 / HER2 Inhibitor:
cFMS Inhibitor (partnered with Celgene):
ARRY-520 / KSP Inhibitor:
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. For more information on Array, please go to www.arraybiopharma.com.
SOURCE: Array BioPharma
Array BioPharma Inc.